French Study In ICU Patients Treated With Tigecycline

Bacterial Infections Clinical Trial

Official title:

French Prospective Observational Study In Intensive Care Unit (ICU) Patients Treated With Tigecycline

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00799591
• Other study ID #: 3074A1-4448
• Secondary ID: B1811030
• Status: Completed
• Phase: N/A
• First received: November 26, 2008
• Last updated: November 15, 2011
• Start date: September 2008
• Est. completion date: May 2010

Study information

• Verified date: September 2011
• Source: Wyeth is now a wholly owned subsidiary of Pfizer
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Institutional Ethical Committee
• Study type: Observational

Clinical Trial Summary

This study will describe clinical outcome and safety data collected prospectively in subjects hospitalized in an intensive care unit (ICU) presenting with an infection for which treatment with tigecycline, alone or in combination, is planned. Data will be collected only from subjects providing informed consent.

Description:

Healthcare visit.

Extension Rationale:

In order to perform the necessary corrective actions required and to secure database consistency, we request an extension for posting of Basic Results due 26-May-2011 for protocol 3074A1-4448 (B1811030), NCT00799591. Our proposed submission date is 14-Sept-2011.

Pfizer acquired Wyeth on October 16, 2009. With regard to this study, our reconciliation of data identified some discrepancies in data listed in the Project database (managed by the CRO) and the Safety Database (managed by Pfizer). We are taking corrective action which involves: sending queries to investigators, collecting corrective signed forms, and implementing changes within the database. We are requesting this extension to complete that work so that the data can be treated as final and the CSR can be completed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 156
• Est. completion date: May 2010
• Est. primary completion date: May 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult men and women (18 years).

• Subjects hospitalized in a medical or surgical intensive care unit (ICU) (on the day of enrolment in the study).

• Subjects treated with tigecycline (first, second or third line), said treatment freely chosen by the participating physician, prior to enrollment in the study.

Exclusion Criteria:

• Subjects participating in another biomedical research study.

• Patient (or legal representative) who has not dated or signed informed consent document.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Bacterial Infections

Intervention

Other:
• Observational study so no intervention in the patient.
Observational study so no intervention in the patient.

Locations

Country	Name	City	State
France	Pfizer Investigational Site	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Wyeth is now a wholly owned subsidiary of Pfizer

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Per Clinical Outcome (Success, Failure, or Undetermined) at End of Treatment (EOT)	Clinical Success: lack of need to use new antibiotic or a surgical treatment not initially planned for initial infection. Failure: persistence of initial infection (required change of antibiotic or surgery), death related to infection (>48 hours after start of treatment with tigecycline), or premature cessation of treatment due to treatment-related Adverse Event. Undetermined: insufficient data for assessment, death not directly related to initial infection, death within first 48 hours of start of treatment with tigecycline, or additional antibiotic treatment for other than initial infection.	End of Treatment (on the day of last dose of study treatment) or up to 25 months	Yes
Primary	Percentage of Participants Per Clinical Outcome (Success, Failure, or Undetermined) at Follow-up Visit	Clinical Success: lack of need to use new antibiotic or a surgical treatment not initially planned for initial infection. Failure: persistence of initial infection (required change of antibiotic or surgery), death related to infection (>48 hours after start of treatment with tigecycline), or premature cessation of treatment due to treatment-related Adverse Event. Undetermined: insufficient data for assessment, death not directly related to initial infection, death within first 48 hours of start of treatment with tigecycline, or additional antibiotic treatment for other than initial infection.	Follow-up Visit (7 days after last dose or at hospital discharge whichever occurred within 7 days after last dose) or up to 25 months	Yes
Secondary	Percentage of Participants Per Tigecycline Loading Dose and Maintenance Dose	Tigecycline powder for solution 50 milligrams (mg) for intravenous (IV) infusion could be administered with an initial loading dose of 100 mg followed by 50 mg administered IV (over 30 to 60 minutes) every 12 hours for 5 to 14 days. Use and dosage recommendations for tigecycline (Tygacil®) were on the basis of the approved Summary of Product Characteristics (SmPC) and adjusted solely according to medical and therapeutic necessity.	Baseline (Inclusion) through last dose of study treatment or up to 25 months	No
Secondary	Mean Duration (Days) of Treatment With Tigecycline		Baseline (Inclusion) through last dose of study treatment or up to 25 months	No
Secondary	Percentage of Participants (> 10%) With Use of Other Antibiotics in Combination With Tigecycline Who Had Clinical Success at EOT	Combinations of antibiotic treatments for participants treated with clinical success with tigecycline. Clinical success defined as lack of need to use new antibiotic or a surgical treatment not initially planned for initial infection.	Baseline (Inclusion), End of Treatment (on the day of last dose of study treatment) or up to 25 months	No
Secondary	Percentage of Participants (> 10%) With Use of Other Antibiotics in Combination With Tigecycline Who Had Clinical Success at Follow-up Visit	Combinations of antibiotic treatments for participants treated with clinical success with tigecycline. Clinical success defined as lack of need to use new antibiotic or a surgical treatment not initially planned for initial infection.	Baseline (Inclusion), Follow-up Visit (7 days after last dose or at hospital discharge whichever occurred within 7 days after last dose) or up to 25 months	No
Secondary	Percentage of Participants With Microbiological Sampling Results During Treatment Phase With Tigecycline: Positive Blood Culture	Microbiological sampling results categorized as a positive blood culture (presence of infection).	Post-baseline (Day 1) through last dose of study treatment or up to 25 months	No
Secondary	Percentage of Participants With Microbiological Sampling Results During Treatment Phase With Tigecycline: Direct Examination	Microbiological sampling results categorized according to direct examination (identification of the class of germs).	Post-baseline (Day 1) through last dose of study treatment or up to 25 months	No

External Links

•   To obtain contact information for a study center near you, click here.